Reports
Reports
Sale
The global liver cancer screening market size reached a value of more than USD 11.99 billion in 2023. The market value is expected to grow at a CAGR of 7.20% in the forecast period of 2024-2032, reaching a value of USD 22.41 billion by 2032.
Cancer is a term used for multiple tumours that can develop in any of the body parts and in the later stages they can spread uncontrollably to the other parts of the body. Among the different types of liver cancer, the most common type of liver cancer is hepatocellular, which starts in the main part of the liver cell called hepatocyte.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
People are increasingly adopting sedentary lifestyles, which has made it more likely for people to have chronic diseases such as hepatitis B or C or fatty liver disease, among many others.
Major players in the market and research institutes are collaborating and increasing their funds to develop new and innovative treatment solutions.
Governments of different countries across the globe are working on boosting their healthcare infrastructure to provide advanced diagnosis and treatment options for patients.
The number of programs is multiplying to raise awareness for early diagnosis of any disorder. This will increase the number of people visiting medical centres, which will propel the market growth.
Developing countries in Asia and Africa lack the technology and experts to manufacture devices themselves. This creates a lucrative opportunity for major players to expand their market in those regions.
The high cost of advanced liver cancer diagnostic devices is a major restraining factor for the market growth in the developing regions.
The lack of proper policies for reimbursement and insurance of diagnostic plans and treatments can hinder the market growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on type, the market can be segmented into hepatocellular carcinoma, cholangiocarcinoma, and hepatoblastoma, among others. Based on the screening, it can be bifurcated into laboratory tests, imaging tests, endoscopy, and biopsy, among others. Based on end-use, the market segments include hospitals and diagnostic laboratories, pharmaceutical and CRO laboratories, and academic and research institutes, among others.
The regional markets for the liver cancer screening market can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
The extensive E.M.R. report provides an in-depth evaluation of the market based on Porter's five forces model and a SWOT analysis
The lever cancer screening market report comprehensively analyses key players in the market, covering their competitive landscape and the latest developments like mergers, acquisitions, investments, and expansion plans.
In the liver cancer screening market, the segments include hepatocellular carcinoma, cholangiocarcinoma, and hepatoblastoma, among others. Among these, hepatocellular carcinoma is the most common type of liver disease and its usually found in people with chronic liver disease or damaged liver due to hepatitis B or C.
Cholangiocarcinoma, also known as Bile Duct Cancer, is a type of cancer disease that develops in the slender tubes in the liver that carries digestive bile fluids. This segment is expected to develop as the ageing population in the world increases.
The market, based on screenings, is segmented into laboratory tests, imaging tests, endoscopy, and biopsy, among others. Among these screenings, imaging tests hold a major share of the market. There are different types of imaging tests including CT (computed tomography) and MRI (magnetic resonance imaging), which are the most common types of imaging.
An imaging test is used by specialists to get pictures of the inside of a body and analyse the condition of the part. These tests are often used for early diagnosis of cancer.
Endoscopy is a non-surgical method of a visual examination of a person’s digestive tract. In this procedure a long, thin tube is directly inserted, with a camera on the tube’s end, to examine the organs and tissue.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
F. Hoffmann-La Roche Ltd is more commonly known as Roche. It is a multinational healthcare company based in Switzerland and founded in 1896. Their primary focus lies around two sectors- pharmaceuticals and diagnostics. They have increased their focus on early detection of diseases and accurate diagnosis to develop personalised healthcare.
Abbott Laboratories is a major player working in the field of healthcare providing solutions and diagnostics, medical devices, and medicines. This American multinational company is headquartered in Illinois, United States.
Siemens Healthineers AG is a German multinational company with a focus on medical devices, founded in 1847. They provide services for in-vitro and in-vivo diagnostics and image-guided therapy. They conduct research and development to develop new and innovative cancer care by combining the latest technologies, like artificial intelligence (AI) and big data.
Koninklijke Philips N.V. is a technology company engaged in multiple fields like healthcare, household electronics, and lighting to improve people’s lifestyle. They provide a wide variety of equipment for diagnosis, including radiography, ultrasound, imaging, and monitoring, among other services.
Becton, Dickinson and Company is a multinational medical technology company that is engaged in improving medical devices, diagnostics, and the manufacturing and distribution of medical devices and reagents. They also provide consulting and analytics services for companies.
REPORT FEATURES | DETAILS |
---|---|
Base Year | 2023 |
Historical Period | 2018-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Type |
|
Breakup by Screening |
|
Breakup by End Use |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Liver Cancer Screening Market Analysis
8.1 Key Industry Highlights
8.2 Global Liver Cancer Screening Historical Market (2018-2023)
8.3 Global Liver Cancer Screening Market Forecast (2024-2032)
8.4 Global Liver Cancer Screening Market by Type
8.4.1 Hepatocellular Carcinoma
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2023)
8.4.1.3 Forecast Trend (2024-2032)
8.4.2 Cholangiocarcinoma
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2023)
8.4.2.3 Forecast Trend (2024-2032)
8.4.3 Hepatoblastoma
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2018-2023)
8.4.3.3 Forecast Trend (2024-2032)
8.4.4 Others
8.5 Global Liver Cancer Screening Market by Screening
8.5.1 Laboratory Tests
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2023)
8.5.1.3 Forecast Trend (2024-2032)
8.5.1.4 Breakup by Type
8.5.1.4.1 Biomarkers
8.5.1.4.2 Blood Tests
8.5.2 Imaging Tests
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2023)
8.5.2.3 Forecast Trend (2024-2032)
8.5.3 Endoscopy
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2018-2023)
8.5.3.3 Forecast Trend (2024-2032)
8.5.4 Biopsy
8.5.4.1 Market Share
8.5.4.2 Historical Trend (2018-2023)
8.5.4.3 Forecast Trend (2024-2032)
8.5.5 Others
8.6 Global Liver Cancer Screening Market by End Use
8.6.1 Hospitals and Diagnostic Laboratories
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2018-2023)
8.6.1.3 Forecast Trend (2024-2032)
8.6.2 Pharmaceutical and CRO Laboratories
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2018-2023)
8.6.2.3 Forecast Trend (2024-2032)
8.6.3 Academic and Research Institutes
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2018-2023)
8.6.3.3 Forecast Trend (2024-2032)
8.6.4 Others
8.7 Global Liver Cancer Screening Market by Region
8.7.1 North America
8.7.1.1 Market Share
8.7.1.2 Historical Trend (2018-2023)
8.7.1.3 Forecast Trend (2024-2032)
8.7.2 Europe
8.7.2.1 Market Share
8.7.2.2 Historical Trend (2018-2023)
8.7.2.3 Forecast Trend (2024-2032)
8.7.3 Asia Pacific
8.7.3.1 Market Share
8.7.3.2 Historical Trend (2018-2023)
8.7.3.3 Forecast Trend (2024-2032)
8.7.4 Latin America
8.7.4.1 Market Share
8.7.4.2 Historical Trend (2018-2023)
8.7.4.3 Forecast Trend (2024-2032)
8.7.5 Middle East and Africa
8.7.5.1 Market Share
8.7.5.2 Historical Trend (2018-2023)
8.7.5.3 Forecast Trend (2024-2032)
9 North America Market Analysis
9.1 United States of America
9.1.1 Market Share
9.1.2 Historical Trend (2018-2023)
9.1.3 Forecast Trend (2024-2032)
9.2 Canada
9.2.1 Market Share
9.2.2 Historical Trend (2018-2023)
9.2.3 Forecast Trend (2024-2032)
10 Europe Market Analysis
10.1 United Kingdom
10.1.1 Market Share
10.1.2 Historical Trend (2018-2023)
10.1.3 Forecast Trend (2024-2032)
10.2 Germany
10.2.1 Market Share
10.2.2 Historical Trend (2018-2023)
10.2.3 Forecast Trend (2024-2032)
10.3 France
10.3.1 Market Share
10.3.2 Historical Trend (2018-2023)
10.3.3 Forecast Trend (2024-2032)
10.4 Italy
10.4.1 Market Share
10.4.2 Historical Trend (2018-2023)
10.4.3 Forecast Trend (2024-2032)
10.5 Others
11 Asia Pacific Market Analysis
11.1 China
11.1.1 Market Share
11.1.2 Historical Trend (2018-2023)
11.1.3 Forecast Trend (2024-2032)
11.2 Japan
11.2.1 Market Share
11.2.2 Historical Trend (2018-2023)
11.2.3 Forecast Trend (2024-2032)
11.3 India
11.3.1 Market Share
11.3.2 Historical Trend (2018-2023)
11.3.3 Forecast Trend (2024-2032)
11.4 ASEAN
11.4.1 Market Share
11.4.2 Historical Trend (2018-2023)
11.4.3 Forecast Trend (2024-2032)
11.5 Australia
11.5.1 Market Share
11.5.2 Historical Trend (2018-2023)
11.5.3 Forecast Trend (2024-2032)
11.6 Others
12 Latin America Market Analysis
12.1 Brazil
12.1.1 Market Share
12.1.2 Historical Trend (2018-2023)
12.1.3 Forecast Trend (2024-2032)
12.2 Argentina
12.2.1 Market Share
12.2.2 Historical Trend (2018-2023)
12.2.3 Forecast Trend (2024-2032)
12.3 Mexico
12.3.1 Market Share
12.3.2 Historical Trend (2018-2023)
12.3.3 Forecast Trend (2024-2032)
12.4 Others
13 Middle East and Africa Market Analysis
13.1 Saudi Arabia
13.1.1 Market Share
13.1.2 Historical Trend (2018-2023)
13.1.3 Forecast Trend (2024-2032)
13.2 United Arab Emirates
13.2.1 Market Share
13.2.2 Historical Trend (2018-2023)
13.2.3 Forecast Trend (2024-2032)
13.3 Nigeria
13.3.1 Market Share
13.3.2 Historical Trend (2018-2023)
13.3.3 Forecast Trend (2024-2032)
13.4 South Africa
13.4.1 Market Share
13.4.2 Historical Trend (2018-2023)
13.4.3 Forecast Trend (2024-2032)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
15 Competitive Landscape
15.1 Market Structure
15.2 Company Profiles
15.2.1 F. Hoffmann-La Roche Ltd
15.2.1.1 Company Overview
15.2.1.2 Product Portfolio
15.2.1.3 Demographic Reach and Achievements
15.2.1.4 Certifications
15.2.2 Abbott Laboratories
15.2.2.1 Company Overview
15.2.2.2 Product Portfolio
15.2.2.3 Demographic Reach and Achievements
15.2.2.4 Certifications
15.2.3 Siemens Healthineers AG
15.2.3.1 Company Overview
15.2.3.2 Product Portfolio
15.2.3.3 Demographic Reach and Achievements
15.2.3.4 Certifications
15.2.4 Koninklijke Philips N.V.
15.2.4.1 Company Overview
15.2.4.2 Product Portfolio
15.2.4.3 Demographic Reach and Achievements
15.2.4.4 Certifications
15.2.5 Becton, Dickinson and Company
15.2.5.1 Company Overview
15.2.5.2 Product Portfolio
15.2.5.3 Demographic Reach and Achievements
15.2.5.4 Certifications
15.2.6 Epigenomics AG
15.2.6.1 Company Overview
15.2.6.2 Product Portfolio
15.2.6.3 Demographic Reach and Achievements
15.2.6.4 Certifications
15.2.7 Thermo Fisher Scientific Corporation
15.2.7.1 Company Overview
15.2.7.2 Product Portfolio
15.2.7.3 Demographic Reach and Achievements
15.2.7.4 Certifications
15.2.8 FUJIFILM Holdings America Corporation
15.2.8.1 Company Overview
15.2.8.2 Product Portfolio
15.2.8.3 Demographic Reach and Achievements
15.2.8.4 Certifications
15.2.9 Others
16 Key Trends and Developments in the Market
List of Figures and Tables
1. Global Liver Cancer Screening Market: Key Industry Highlights, 2018 and 2032
2. Global Liver Cancer Screening Historical Market: Breakup by Type (USD Billion), 2018-2023
3. Global Liver Cancer Screening Market Forecast: Breakup by Type (USD Billion), 2024-2032
4. Global Liver Cancer Screening Historical Market: Breakup by Screening (USD Billion), 2018-2023
5. Global Liver Cancer Screening Market Forecast: Breakup by Screening (USD Billion), 2024-2032
6. Global Liver Cancer Screening Historical Market: Breakup by End Use (USD Billion), 2018-2023
7. Global Liver Cancer Screening Market Forecast: Breakup by End Use (USD Billion), 2024-2032
8. Global Liver Cancer Screening Historical Market: Breakup by Region (USD Billion), 2018-2023
9. Global Liver Cancer Screening Market Forecast: Breakup by Region (USD Billion), 2024-2032
10. North America Liver Cancer Screening Historical Market: Breakup by Country (USD Billion), 2018-2023
11. North America Liver Cancer Screening Market Forecast: Breakup by Country (USD Billion), 2024-2032
12. Europe Liver Cancer Screening Historical Market: Breakup by Country (USD Billion), 2018-2023
13. Europe Liver Cancer Screening Market Forecast: Breakup by Country (USD Billion), 2024-2032
14. Asia Pacific Liver Cancer Screening Historical Market: Breakup by Country (USD Billion), 2018-2023
15. Asia Pacific Liver Cancer Screening Market Forecast: Breakup by Country (USD Billion), 2024-2032
16. Latin America Liver Cancer Screening Historical Market: Breakup by Country (USD Billion), 2018-2023
17. Latin America Liver Cancer Screening Market Forecast: Breakup by Country (USD Billion), 2024-2032
18. Middle East and Africa Liver Cancer Screening Historical Market: Breakup by Country (USD Billion), 2018-2023
19. Middle East and Africa Liver Cancer Screening Market Forecast: Breakup by Country (USD Billion), 2024-2032
20. Global Liver Cancer Screening Market Structure
In 2023, the market attained a value of USD 11.99 billion, driven by the rising number of cases.
The market for lung cancer screening is expected to grow at a CAGR of 7.20% during the period 2024-2032.
The market is expected to reach a value of USD 22.41 billion by 2032.
The liver cancer screening market is driven by the rising cases of chronic liver disorders and increasing efforts in research and development.
The rising early health diagnosis awareness and increasing government efforts to develop healthcare services and promotion of better services to increase awareness are key trends in the market.
The regional markets for the global lung therapeutics market include North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa
The types of cancer in the market for liver cancer screening include hepatocellular carcinoma, cholangiocarcinoma, and hepatoblastoma, among others.
The market segments for liver cancer screening, based on screening, include laboratory tests, imaging tests, endoscopy, and biopsy, among others.
Based on end-use, the market segments include hospitals and diagnostic laboratories, pharmaceutical and CRO laboratories, academic and research institutes, among others.
Alpha-fetoprotein (AFP) is the most widely used method for detecting liver cancer.
A CT scan can give detailed images of your internal organs and help in acquiring different information like the size, shape, and location of the tumour.
The key players in the market include F. Hoffmann-La Roche Ltd, Abbott Laboratories, Siemens Healthineers AG, Koninklijke Philips N.V., Becton, Dickinson and Company, Epigenomics AG, Thermo Fisher Scientific Corporation, and FUJIFILM Holdings America Corporation, among others.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.